Quick answer
Severe mitral regurgitation in older, frail patients often cannot be fixed surgically, and edge-to-edge repair does not suit every anatomy. Transcatheter mitral valve replacement (TMVR) replaces the whole valve instead. Zhang Haibo's team at Beijing Anzhen Hospital reported one-year follow-up of 16 consecutive high-risk patients treated with a domestic TMVR system: 100% procedural success, 81.2% one-year survival, and durable regurgitation control in survivors [1][2].
Key takeaways
- 16 consecutive patients with severe degenerative mitral regurgitation (MR ≥3+), enrolled June 2021 to July 2022 [2].
- Procedural success 100%; 30-day mortality 2/16 (12.5%) [2].
- One-year all-cause mortality 3/16 (18.8%), all cardiovascular; one-year survival 81.2% [2].
- Among 13 one-year survivors, 12 (92.3%) had MR ≤1+ with no device-related complications [2].
- Function and quality of life improved: NYHA I/II from 12.5% to 76.9%; KCCQ from 57.5 to 83.8; six-minute walk from 285 m to 413 m [2].
Why replace rather than repair
Transcatheter edge-to-edge repair (TEER) is the established catheter option for mitral regurgitation, but it clips the leaflets rather than replacing the valve, and complex degenerative anatomy or a large coaptation gap can limit its effect. TMVR removes the leaflets from the equation — at the cost of a larger device, more anatomical screening and the risk of outflow obstruction [1][2].
The device studied is a Chinese-origin system; Anzhen's team, led by Hu Shengshou at the institutional level, has been running its registration trial. The report is a single-centre brief communication covering the first consecutive cohort [2][3]. The device is one of several Chinese TMVR systems in development; using ultrasound rather than fluoroscopy as the primary imaging guide is part of its design claim, which matters in hospitals without a hybrid theatre [4][5].
Reading the numbers
Two deaths in the first 30 days — one from acute heart failure on day 7 and one from cardiogenic shock on day 15 — reflect how ill these patients were at baseline. An 18.8% one-year mortality in a cohort deemed inoperable is comparable with international TMVR registries, though direct comparison is difficult. The functional gains are large: three-quarters of survivors moved to NYHA class I or II, and the six-minute walk distance rose by more than 120 metres [2].
Sixteen patients cannot establish that TMVR is better than TEER or medical therapy, and there was no control group. Two patients were readmitted for heart failure at three to six months, which shows the limit of the procedure in advanced disease. Longer follow-up is needed for valve durability and for the risk of left ventricular outflow tract obstruction [1][2].
The condition in context: mitral regurgitation
Mitral regurgitation is the most common valve disease, and untreated severe disease carries high mortality.
| Region | What the data shows | Source |
|---|---|---|
| Prevalence | About 1.7% of the general population has mitral regurgitation [2]. | JACC: Asia summary [2] |
| Untreated | Severe symptomatic patients who go unoperated have about 39% five-year all-cause mortality [2]. | JACC: Asia summary [2] |
| Treatment gap | Many are too old or frail for surgery, and TEER does not suit all anatomy [1][2]. | Yandao [1] |
Because the alternative for these patients is often medical therapy alone, a catheter replacement that works has clear value — if durability holds [2].
Why it matters
| Potential | What the report suggests | Source |
|---|---|---|
| Regurgitation control | 92.3% of survivors at MR ≤1+ [2]. | [2] |
| Function | Large gains in NYHA class, KCCQ and walking distance [2]. | [2] |
| Caution | Small single-centre cohort; mortality 18.8% at one year [1]. | [1] |
Availability and limits
- This is an editorial summary of a published brief report, not a treatment recommendation [1][2].
- Only 16 patients, one centre, no comparator [2].
- The device is in clinical trials in China; broader approval is not described [3].
- Screening for outflow obstruction and annular anatomy is essential [2].
- Long-term durability beyond one year is unknown [1][5].
What to ask before booking
| Question | Why it matters |
|---|---|
| Is my anatomy suitable for TMVR rather than TEER? | Annular size and outflow risk decide the route [2]. |
| Is the device available inside or outside a trial? | Access is still limited [3]. |
| Which department handles foreign patients, and in what language? | Anzhen is a working hospital we do not book; confirm international-department coordination and language support. |
| What follow-up is required? | Valve durability and heart failure need monitoring [1]. |
Questions patients ask
What was reported?
One-year outcomes in 16 high-surgical-risk patients with severe degenerative mitral regurgitation treated with a domestic TMVR system: 100% procedural success, 81.2% one-year survival, 92.3% of survivors at MR ≤1+ [1][2].
Where was it published?
JACC: Asia, as a brief report [1][2].
How does TMVR differ from TEER?
TEER clips the leaflets; TMVR replaces the valve, which suits some anatomies better but requires more screening [1][2].
Is the device approved?
It is in clinical trials in China; broad approval is not described [3].
Is this relevant to international patients?
It is useful context for China's structural heart programme. Anzhen is a working hospital we do not book — contact its international department directly [1].